GLP-1 receptor agonists – Page 3

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

By MedXY 08/31/2025

GLP-1 receptor agonists, used for obesity and type 2 diabetes management, are linked to a 17% lower overall cancer risk, notably hormone-sensitive cancers, but may increase kidney cancer risk. Further research is needed to clarify safety and mechanisms.

Clinical Updates Diabetes & Endocrinology Specialties

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

By MedXY 08/23/2025

Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.

Clinical Updates Diabetes & Endocrinology news Specialties

GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation

By MedXY 07/31/2025

A large-scale emulated trial found no clear overall reduction in dementia risk with GLP-1 receptor agonists versus DPP-4 inhibitors in older adults with type 2 diabetes, though age-specific effects warrant further investigation.